UPDATE: Morgan Stanley Upgrades Abbott Laboratories
January 17, 2014 at 07:55 AM EST
In a report published Friday, Morgan Stanley analyst David Lewis upgraded Abbott Laboratories (NYSE: ABT ) to Overweight, with a $45.00 price target. According to the report, the upgrade reflects growth and leverage prospects into 2H14 and 2015 are underappreciated. Guidance for 2014 likely includes known headwinds FX, Nutrition
